Oral and gastric contributions to satiety II: effects of energy content.
- Conditions
- overweight and obesityobesityoverweight
- Registration Number
- NL-OMON36467
- Lead Sponsor
- estec
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 40
Male, healthy (based on subjects own judgement), aged between 18 and 40 years, BMI between 18.5 and 25 kg/m2, stable body weight (no changes larger than 5kg over the past 2 months)
• Smoking or drug use
• Taking any medication, except for light pain relieving medications which are available over the counter (aspirin or paracetamol).
• Gastro-intestinal diseases
• Diabetes, thyroid diseases or any other endocrine disorders
• Problems with the respiratory tract, such as hyperventilation, asthma or bronchitis, which can cause problems when the naso-gastric tube is inserted.
• Lack of appetite for any reason
• Restraint eating DEBQ score >= 2.26 (above average)
• Hypersensitivity or food allergy for products used in this study
• Currently participating or having participated in a clinical trial during the last 3 months prior to the beginning of this study.
• Working at, or doing an MSc. thesis at the Division of Human Nutrition
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The primary outcome is ad libitum energy intake of an ad libitum test meal<br /><br>served 30 minutes after start of the oral exposure/ intragastric infusion. To<br /><br>measure energy intake, the amount of provided food will be determined, as well<br /><br>as the leftovers. Chemical analyses will be performed to determine the exact<br /><br>energy and macronutrient content of the lunch.</p><br>
- Secondary Outcome Measures
Name Time Method